Dextran-spermine polycation: An efficient nonviral vector for in vitro and in vivo gene transfection

H. Hosseinkhani, T. Azzam, Y. Tabata, A. J. Domb

Research output: Contribution to journalArticlepeer-review

156 Scopus citations

Abstract

Dextran-spermine cationic polysaccharide was prepared by means of reductive amination between oxidized dextran and the natural oligoamine spermine. The formed Schiff-base imine-based conjugate was reduced with borohydride to obtain the stable amine-based conjugate. The transfection efficiency of the synthetic dextran-spermine was assessed in vitro on HEK293 and NIH3T3 cell lines and found to be as high as the DOTAP/Chol 1/1 lipid-based transfection reagent. Modification of the dextran-spermine polycation with polyethylene glycol resulted in high transfection yield in serum-rich medium. Intramuscular injection in mice of dextran-spermine-pSV-LacZ complex induced high local gene expression compared to low expression of the naked DNA. Intravenous injection of a dispersion of the dextran-spermine-pSV-LacZ complex resulted with no expression in all examined organs. When the partially PEGylated dextran-spermine-pSV-LacZ complex was intravenously applied, a high gene expression was detected mainly in the liver. Preliminary targeting studies indicated that the PEGylated dextran-spermine-pSV-LacZ complex bound to galactose receptor of liver parenchymal cells rather than the mannose receptor of liver nonparenchymal cells. This work offers a new biodegradable polycation based on natural components, which is capable of transfecting cells and tissues in vitro and in vivo.

Original languageEnglish
Pages (from-to)194-203
Number of pages10
JournalGene Therapy
Volume11
Issue number2
DOIs
StatePublished - Jan 2004
Externally publishedYes

Bibliographical note

Funding Information:
Tony Azzam is grateful to the Ministry of Science, Israel, for its generous financial assistance. This work was supported in part by the AFIRST, French–Israeli Co-operation on Gene Therapy, and by the US–Israel Binational Fund (BSF).

Funding

Tony Azzam is grateful to the Ministry of Science, Israel, for its generous financial assistance. This work was supported in part by the AFIRST, French–Israeli Co-operation on Gene Therapy, and by the US–Israel Binational Fund (BSF).

FundersFunder number
AFIRST
French–Israeli Co-operation on Gene Therapy
Ministry of Science, Israel
US–Israel Binational Fund
United States-Israel Binational Science Foundation

    Keywords

    • Dextran-spermine
    • Gene delivery
    • In vivo
    • PEG
    • Polycation
    • Transfection

    Fingerprint

    Dive into the research topics of 'Dextran-spermine polycation: An efficient nonviral vector for in vitro and in vivo gene transfection'. Together they form a unique fingerprint.

    Cite this